ClinicalTrials.gg
CompletedNCT00385697Updated Dec 5, 2023Results posted

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

A Phase 2/3 interventional study of Teplizumab and Placebo in Type 1 Diabetes Mellitus, sponsored by MacroGenics. Completed at 115 sites in 16 countries. Open to participants aged 8 Years to 35 Years. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by MacroGenics · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
554
Allocation
Randomized
Ages
8 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.

Enrollment
2nd of 11
554 · median 60
Started
2006
the only one that year
Phase 2/3
Only one
of the 11
Registered
1st of 11
by date
Lead sponsor
2 of 11
MacroGenics

Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is the only one that started in 2006, is the only one in phase 2/3, and was the 1st registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teplizumab

teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 8 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing teplizumab in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The primary purpose of this protocol is to assess the efficacy, tolerability, and safety of MGA031 when administered according to 3 different MGA031 dosing regimens in children and adults with recent-onset (diagnosis within past 12 weeks) type 1 diabetes mellitus. All regimens will be administered as an addition to insulin and other standard of care treatments. Efficacy will be defined primarily by the capacity of MGA031 to markedly reduce typical insulin requirements while maintaining relatively normal blood sugar levels.

Other studies involving the study drug use the name hOKT3γ1 (Ala-Ala). MGA031, a humanized monoclonal antibody, is the name used for hOKT3γ1 (Ala-Ala) that is produced by MacroGenics, Inc. The United States Adopted Name (USAN) for MGA031 is teplizumab.

Read the detailed description

The Protégé Study - A Multinational Clinical Trial of MGA031 for Preserving the Capability to Produce Insulin, Reducing Insulin Usage and Improving Blood Sugar Levels in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Randomized
  • Double Blind
  • Parallel Group
  • Controlled Clinical Trial
04

Who can participate

Ages eligible
8 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following criteria:

  1. Enrollment (Segment #1) or randomization (Segment #2) on Study Day 0 within 12 weeks of first visit to any physician for symptoms or signs of diabetes. Study Day 0 is the first day of study drug dosing.
  2. Diagnosis of type 1 diabetes mellitus, according to the American Diabetes Association (ADA) criteria
  3. Requirement for injected insulin therapy
  4. Have a detectable fasting or stimulated C-peptide level (above the lower limit of detection of the assay)
  5. One positive result on testing for any of the following antibodies:

    1. islet-cell autoantibodies (ICA512/IA-2),
    2. glutamic acid decarboxylase autoantibodies, or
    3. insulin autoantibodies (if present during first 2 weeks, but not beyond 2 weeks, of insulin treatment)
  6. Male or female
  7. Subject must be in one of the following age groups:

    • Age 18-35 years
    • Age 12-17 years pending approval by Data Monitoring Committee
    • Age 8-11 years pending approval by Data Monitoring Committee
  8. Body weight ≥ 36 kg

Exclusion criteria

Exclusion Criteria:

Subjects must have none of the following:

  1. Prior administration of a monoclonal antibody -- within the 1 year before enrollment or randomization at Study Day 0 -- that could potentially prevent or confound a therapeutic response to MGA031
  2. Participation in any type of therapeutic drug or vaccine clinical trial within the 12 weeks before enrollment or randomization
  3. Any medical condition that, in the opinion of the investigator, would interfere with safe completion of the trial
  4. Pregnant or lactating females
  5. Prior murine OKT®3 treatment at any time before enrollment or randomization
  6. Current or planned therapy with exenatide or any other agents that stimulate pancreatic beta cell regeneration or insulin secretion
  7. Current or planned therapy with inhaled insulin
  8. Uncompensated heart failure, fluid overload, myocardial infarction or evidence of ischemic heart disease, or other serious cardiac disease within the 12 weeks before enrollment or randomization
  9. History of epilepsy, cancer, cystic fibrosis, sickle cell anemia, neuropathy, peripheral vascular disease or cerebrovascular disease
  10. Newly diagnosed hypothyroidism (not currently being treated but which, in the opinion of the investigator, should be treated) or active Graves' disease
  11. Eczema, asthma or severe atopic disease requiring treatment within the 12 weeks before enrollment or randomization
  12. Evidence of active infection, such as fever ≥ 38.0 degrees Celsius (100.5 degrees Fahrenheit)
  13. Known or suspected infection with (HIV)
  14. Evidence of active (HBV) or virus (HCV)
  15. Evidence of active or latent tuberculosis
  16. Vaccination with a live virus within the 8 weeks before enrollment or randomization or planned continuing through week 52 of the study. Vaccination with an antigen or killed organism must not be given within 8 weeks before or planned within 8 weeks after each dosing cycle.
  17. Any infectious mononucleosis-like illness within the 6 months before enrollment or randomization
  18. Serologic and clinical evidence of acute infection with Epstein-Barr virus (EBV)
  19. Serologic evidence of acute infection with cytomegalovirus (CMV)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
554 participants (actual)

Study arms

  • Experimental
    Double-blind Herold Regimen

    Full dose of teplizumab IV for 14 days, repeated at Week 26

    Biological: Teplizumab

  • Experimental
    Double-blind 33.3% Herold Regimen

    One third full dose of teplizumab IV for 14 days, repeated at Week 26

    Biological: Teplizumab

  • Experimental
    Double-blind Curtailed Herold Regimen

    Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26

    Biological: Teplizumab

  • Placebo comparator
    Double-blind Placebo

    Placebo IV dosing daily for 14 days repeated at Week 26

    Drug: Placebo

  • Experimental
    Open-label Herold Regimen

    Full dose of teplizumab IV for 14 days, repeated at Week 26

    Biological: Teplizumab

Interventions

  • BiologicalTeplizumab

    Daily IV dosing for 14 days, repeated at Week 26

    Also known as: MGA031

  • DrugPlacebo

    Daily IV dosing for 14 days, repeated at Week 26

06

What researchers measure

Primary outcomes

  1. Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.

    This is a composite endpoint is based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5% at 52 weeks after randomization.

    Time frame: 52 weeks after randomization

  2. Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.

    This is a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%

    Time frame: 52 weeks after first dose

  3. Mean HbA1c Change From Baseline in Segment 2

    Comparison among study treatments of average change from baseline HbA1C. This endpoint will be assessed in a hierarchical manner only if the composite primary endpoint shows a statistically significant difference between arms

    Time frame: 52 weeks after randomization

  4. Mean HbA1c Change From Baseline in Segment 1

    The average change in HbA1c levels after dosing.

    Time frame: 52 weeks after first dose

Secondary outcomes

  1. Change From Baseline in C-peptide Area Under the Curve (AUC) in Segment 2

    Comparison among study treatments on the AUC of C-peptide secretory responses following a mixed meal eaten by the subject

    Time frame: 104 weeks after randomization

  2. Change From Baseline in C-peptide AUC in Segment 1

    AUC of C-peptide secretory responses following a mixed meal eaten by the subject

    Time frame: 104 weeks after first dose

  3. Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5%

    Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%.

    Time frame: 104 weeks after randomization

  4. Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5%

    Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%.

    Time frame: 104 weeks after first dose

  5. Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%.

    Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 7.0%.

    Time frame: at 52 weeks after randomization

  6. Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%.

    Composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 7.0%.

    Time frame: 52 weeks after first dose

  7. Mean HbA1c Change From Baseline in Segment 2

    Comparison among study treatments of the average change from baseline in HbA1c.

    Time frame: at 104 weeks after randomization

  8. Mean HbA1c Change From Baseline in Segment 1

    Comparison among study treatments of the average change from baseline in HbA1c.

    Time frame: 104 weeks after first dose

07

Results

Posted Dec 5, 2023

Participant flow

Open-label Segment 1
Participant flow — Open-label Segment 1
MilestoneOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
Started380000
Completed350000
Not completed30000
Withdrew: Withdrawal by subject20000
Withdrew: Lost to follow-up10000
Double-blind Segment 2
Participant flow — Double-blind Segment 2
MilestoneOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
Started020910210699
Full analysis set (fas) population020710210698
Safety population020710210698
Completed0183909792
Not completed0261297
Withdrew: Adverse event03100
Withdrew: Lost to follow-up011525
Withdrew: Withdrawal by subject010672
Withdrew: Other02000
Long-term Follow up Segment 3
Participant flow — Long-term Follow up Segment 3
MilestoneOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
Started35183909792
Completed35183909792
Not completed00000

Outcome measures

PrimaryNumber of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.

This is a composite endpoint is based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5% at 52 weeks after randomization.

Time frame:
52 weeks after randomization
Reported as:
Count of participants · Participants
Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.
ParticipantsOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.—41142220
Statistical analysis
  • Double-blind Herold Regimen vs Double-blind Placebo · Mantel Haenszel · p = 0.904 · Odds ratio (or): 0.963 · 95% CI 0.521 to 1.779
  • Double-blind 33.3% Herold Regimen vs Double-blind Placebo · Mantel Haenszel · p = 0.222 · Odds ratio (or): 0.629 · 95% CI 0.297 to 1.330
  • Double-blind Curtailed Herold Regimen vs Double-blind Placebo · Mantel Haenszel · p = 0.885 · Odds ratio (or): 1.054 · 95% CI 0.521 to 2.129
PrimaryNumber of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.

This is a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%

Time frame:
52 weeks after first dose
Reported as:
Count of participants · Participants
Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.
ParticipantsOpen-label Herold Regimen
Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.11
PrimaryMean HbA1c Change From Baseline in Segment 2

Comparison among study treatments of average change from baseline HbA1C. This endpoint will be assessed in a hierarchical manner only if the composite primary endpoint shows a statistically significant difference between arms

Time frame:
52 weeks after randomization
Reported as:
Mean · percentage of HbA1c
Mean HbA1c Change From Baseline in Segment 2
percentage of HbA1cOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
Mean HbA1c Change From Baseline in Segment 2—-0.42 ± 2.285-0.34 ± 2.196-0.36 ± 2.132-0.43 ± 2.668
Statistical analysis
  • Double-blind Herold Regimen vs Double-blind Placebo · ANCOVA · p = 0.814 · Mean difference (final values): 0.061 · 95% CI -0.450 to 0.572
  • Double-blind 33.3% Herold Regimen vs Double-blind Placebo · ANCOVA · p = 0.593 · Mean difference (final values): 0.161 · 95% CI -0.433 to 0.755
  • Double-blind Curtailed Herold Regimen vs Double-blind Placebo · ANCOVA · p = 0.886 · Mean difference (final values): -0.40 · 95% CI -0.594 to 0.513
PrimaryMean HbA1c Change From Baseline in Segment 1

The average change in HbA1c levels after dosing.

Time frame:
52 weeks after first dose
Reported as:
Mean · percent HbA1c
Mean HbA1c Change From Baseline in Segment 1
percent HbA1cOpen-label Herold Regimen
Mean HbA1c Change From Baseline in Segment 10.25 ± 2.053
SecondaryChange From Baseline in C-peptide Area Under the Curve (AUC) in Segment 2

Comparison among study treatments on the AUC of C-peptide secretory responses following a mixed meal eaten by the subject

Time frame:
104 weeks after randomization
Reported as:
Mean · min*nmol/L
Change From Baseline in C-peptide Area Under the Curve (AUC) in Segment 2
min*nmol/LOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
Change From Baseline in C-peptide Area Under the Curve (AUC) in Segment 2—-0.18 ± 0.355-0.27 ± 0.318-0.20 ± 0.354-0.22 ± 0.428
Statistical analysis
  • Double-blind Herold Regimen · ANCOVA · p = 0.049 · Mean difference (final values): 0.047 · 95% CI 0.000 to 0.093
  • Double-blind 33.3% Herold Regimen vs Double-blind Placebo · ANCOVA · p = 0.937 · Mean difference (final values): -0.002 · 95% CI -0.061 to 0.056
  • Double-blind Curtailed Herold Regimen vs Double-blind Placebo · ANCOVA · p = 0.382 · Mean difference (final values): 0.026 · 95% CI -0.032 to 0.084
SecondaryChange From Baseline in C-peptide AUC in Segment 1

AUC of C-peptide secretory responses following a mixed meal eaten by the subject

Time frame:
104 weeks after first dose
Reported as:
Mean · min*nmol/L
Change From Baseline in C-peptide AUC in Segment 1
min*nmol/LOpen-label Herold Regimen
Change From Baseline in C-peptide AUC in Segment 1-0.45 ± 0.451
SecondaryNumber of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5%

Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%.

Time frame:
104 weeks after randomization
Reported as:
Count of participants · Participants
Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5%
ParticipantsOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5%—176109
Statistical analysis
  • Double-blind Herold Regimen vs Double-blind Placebo · Mantel Haenszel · p = 0.775 · Odds ratio (or): 0.881 · 95% CI 0.372 to 2.089
  • Double-blind 33.3% Herold Regimen vs Double-blind Placebo · Mantel Haenszel · p = 0.402 · Odds ratio (or): 0.628 · 95% CI 0.212 to 1.861
  • Double-blind Curtailed Herold Regimen vs Double-blind Placebo · Mantel Haenszel · p = 0.859 · Odds ratio (or): 1.093 · 95% CI 0.410 to 2.912
SecondaryNumber of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5%

Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%.

Time frame:
104 weeks after first dose
Reported as:
Count of participants · Participants
Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5%
ParticipantsOpen-label Herold Regimen
Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5%5
SecondaryNumber of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%.

Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 7.0%.

Time frame:
at 52 weeks after randomization
Reported as:
Count of participants · Participants
Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%.
ParticipantsOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%.—60212824
Statistical analysis
  • Double-blind Herold Regimen vs Double-blind Placebo · Mantel Haenszel · p = 0.404 · Odds ratio (or): 1.265 · 95% CI 0.727 to 2.200
  • Double-blind 33.3% Herold Regimen vs Double-blind Placebo · Mantel Haenszel · p = 0.528 · Odds ratio (or): 0.805 · 95% CI 0.412 to 1.576
  • Double-blind Curtailed Herold Regimen vs Double-blind Placebo · Mantel Haenszel · p = 0.706 · Odds ratio (or): 1.133 · 95% CI 0.594 to 2.164
SecondaryNumber of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%.

Composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 7.0%.

Time frame:
52 weeks after first dose
Reported as:
Count of participants · Participants
Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%.
ParticipantsOpen-label Herold Regimen
Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%.14
SecondaryMean HbA1c Change From Baseline in Segment 2

Comparison among study treatments of the average change from baseline in HbA1c.

Time frame:
at 104 weeks after randomization
Reported as:
Mean · percent of HbA1c
Mean HbA1c Change From Baseline in Segment 2
percent of HbA1cOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
Mean HbA1c Change From Baseline in Segment 2—0.14 ± 2.4110.08 ± 2.2610.04 ± 2.2080.16 ± 2.510
Statistical analysis
  • Double-blind Herold Regimen vs Double-blind Placebo · ANCOVA · p = 0.872 · Mean difference (final values): 0.040 · 95% CI -0.455 to 0.536
  • Double-blind 33.3% Herold Regimen vs Double-blind Placebo · ANCOVA · p = 0.979 · Mean difference (final values): -0.008 · 95% CI -0.581 to 0.556
  • Double-blind Curtailed Herold Regimen vs Double-blind Placebo · ANCOVA · p = 0.400 · Mean difference (final values): -0.225 · 95% CI -0.750 to 0.301
SecondaryMean HbA1c Change From Baseline in Segment 1

Comparison among study treatments of the average change from baseline in HbA1c.

Time frame:
104 weeks after first dose
Reported as:
Mean · percentage of HbA1c
Mean HbA1c Change From Baseline in Segment 1
percentage of HbA1cOpen-label Herold Regimen
Mean HbA1c Change From Baseline in Segment 10.73 ± 2.091

Adverse events

Collected over Adverse events (AE), serious adverse events (SAE), and adverse events of special interest (AESI) were collected through Week 52. Only SAE and AESI were collected after Week 53 through Week 104.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label Herold Regimen0/38 (0%)6/38 (15.8%)38/38 (100%)
Double-blind Herold Regimen1/207 (0.5%)23/207 (11.1%)207/207 (100%)
Double-blind 33.3% Herold Regimen1/102 (1%)14/102 (13.7%)101/102 (99%)
Double-blind Curtailed Herold Regimen0/106 (0%)12/106 (11.3%)105/106 (99.1%)
Double-blind Placebo0/98 (0%)12/98 (12.2%)98/98 (100%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
Diabetic ketoacidosisMetabolism and nutrition disorders2/386/2073/1022/1060/98
GastritisGastrointestinal disorders1/380/2071/1020/1060/98
Cytokine release syndromeImmune system disorders1/380/2070/1020/1060/98
Dengue feverInfections and infestations1/380/2070/1020/1060/98
Hepatitis AInfections and infestations1/380/2070/1020/1060/98
PharyngotonsillitisInfections and infestations1/380/2070/1020/1060/98
HyperglycaemiaMetabolism and nutrition disorders1/381/2071/1021/1061/98
KetonuriaRenal and urinary disorders1/380/2070/1020/1060/98
RashSkin and subcutaneous tissue disorders1/381/2070/1020/1060/98
KeytonuriaRenal and urinary disorders1/380/2070/1020/1060/98
Most frequent other events
Showing 10 of 90
Most frequent other events
EventOpen-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind Placebo
LymphopeniaBlood and lymphatic system disorders36/38152/20767/10281/10617/98
LeukopeniaBlood and lymphatic system disorders25/38101/20749/10250/10622/98
Blood bicarbonate decreasedInvestigations13/3892/20760/10241/10638/98
Aspartate aminotransferase increasedInvestigations17/3873/20728/10237/10633/98
RashSkin and subcutaneous tissue disorders17/3865/20744/10237/10611/98
Alanine aminotransferase increasedInvestigations16/3871/20726/10231/10617/98
White blood cell count decreasedInvestigations15/3886/20732/10241/10618/98
NeutropeniaBlood and lymphatic system disorders15/3871/20733/10222/10618/98
Haemoglobin decreasedInvestigations14/3866/20729/10234/10632/98
HyponatraemiaMetabolism and nutrition disorders8/3864/20735/10238/10634/98

Baseline characteristics

Baseline characteristics for age, six, race and ethnicity are from the FAS, which includes only those participants enrolled and receiving study treatment (n=551). There were 3 participants enrolled who were never dosed so they are excluded from the FAS.

Age, Continuous
Age, Continuous(years)Open-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind PlaceboTotal
Median13.5 (10.0 to 34.0)17 (8 to 35)17 (8 to 34)16 (8 to 33)17 (8 to 34)17 (8 to 35)
Age, Customized
Age, Customized(Participants)Open-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind PlaceboTotal
age 8-11 years113115161588
age 12-17 years1681424438221
age 18-35 years1195454645242
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind PlaceboTotal
Female877403437196
Male30130627261355
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Open-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind PlaceboTotal
Hispanic or Latino214712540
Not Hispanic or Latino36193959493511
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind PlaceboTotal
American Indian or Alaska Native000000
Asian559282927148
Native Hawaiian or Other Pacific Islander000000
Black or African American000112
White33145747569396
More than one race000000
Unknown or Not Reported030115
Region of Enrollment
Region of Enrollment(participants)Open-label Herold RegimenDouble-blind Herold RegimenDouble-blind 33.3% Herold RegimenDouble-blind Curtailed Herold RegimenDouble-blind PlaceboTotal
Romania4754424
United States2064323131178
Czechia81275638
Ukraine0181091047
Spain0633315
India559282928149
Canada1614113
Sweden000101
Latvia031217
Poland01056425
Mexico0945422
Israel01166629
Germany020002
Estonia020114
08

Study locations

115 sites
  • UAB School of Medicine
    Birmingham, Alabama 35294, United States
  • NEA Clinic
    Jonesboro, Arkansas 72401, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Diabetes Medical Center of California
    Northridge, California 91325, United States
  • UCSF Medical Center
    San Francisco, California 94143, United States
  • University of Colorado Health Sciences Center
    Aurora, Colorado 80045, United States
  • Yale University
    New Haven, Connecticut 06519, United States
  • Christiana Care Research Institute
    Newark, Delaware 19713, United States
  • Richard Hays, MD
    Wellington, Florida 33414, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30309, United States
  • Humphrey Diabetes Center
    Boise, Idaho 87702, United States
  • Rocky Mountain Diabetes & Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242-1083, United States
  • Mid-America Diabetes Associates, PA
    Wichita, Kansas 67211, United States
  • Commonwealth Biomedical Research, LLC
    Madisonville, Kentucky 42431, United States
  • St. Agnes Hospital
    Baltimore, Maryland 21229, United States
  • Maryland Diabetes & Endocrine Associates
    Rockville, Maryland 20852, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • Alzohaili Medical Consultants
    Dearborn, Michigan 48126, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Creighton Diabetes Center
    Omaha, Nebraska 68131, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • University of Medicine & Dentistry of NJ
    New Brunswick, New Jersey 08901, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Schneider Children's Hospital
    New Hyde Park, New York 11040, United States
  • Joslin Diabetes Center
    Syracuse, New York 13214, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • St. Mary Medical Center
    Langhorne, Pennsylvania 19047, United States
  • Sumter Medical Specialists
    Sumter, South Carolina 29150, United States
  • University Diabetes & Endocrine Consultants
    Chattanooga, Tennessee 37403, United States
  • Methodist Healthcare
    Memphis, Tennessee 38104, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • Spectra Research Center
    McAllen, Texas 78503, United States
  • Diabetes and Glandular Disease Research
    San Antonio, Texas 78229, United States
  • Endocrine Research Specialists
    Ogden, Utah 84403, United States
  • Pacific Northwest Research Institute
    Seattle, Washington 98122, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
  • University of Manitoba
    Winnipeg, Manitoba R3E0Z2, Canada
  • University Health Sciences Centre
    St. John's, Newfoundland and Labrador A1B3V6, Canada
  • Capital District Health Authority
    Halifax, Nova Scotia B3H2YN, Canada
  • Oxford AIM Clinic
    London, Ontario N6A 5R9, Canada
  • Children's Hospital of Western
    London, Ontario N6A5W9, Canada
  • FN Brno- Detska nemocnice
    Brno, 62500, Czechia
  • FN Hradec Kralove
    Hradec Kralove, 50005, Czechia
  • Nemocnice Jihlava
    Jihlava, 58633, Czechia
  • FN Kralovske Vinohrady
    Praha 10, 10034, Czechia
  • Fakultni nemocnice v Motole
    Praha, 150 06, Czechia
  • Masarykova nemocnice v Usti nad Labem
    Usti nad Labem, 40113, Czechia
  • Tartu University Hospital
    Puusepa, Tartu 51014, Estonia
  • East Tallinn Central Hospital
    Tallinn, Estonia
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Medizinische Universitätsklinik Ulm
    Ulm, Baden-Wurttemberg 89070, Germany
  • Herz-und Diabetszentrum Nordrhein-Westfalen
    Bad Oeynhausen, North Rhine-Westphalia 32545, Germany
  • Charité-Hochschulmedizin Berlin
    Berlin, 12200, Germany
  • Universitatsklinik Giessen
    Giessen, 35392, Germany
  • Nizam's Institute of Medical Sciences
    Hyderabad, Andhra Pradesh 500082, India
  • King George Hospital
    Visakhapatnam, Andhra Pradesh 530002, India
  • Gujarat Endocrine Centre
    Ahmedabad, Gujarat 380006, India
  • DHL Research Centre
    Ahmedabad, Gujarat 380015, India
  • Bharti Research Institute of Diabetes & Endocrinology
    Karnal, Haryana 132001, India
  • Bangalore Diabetes Centre
    Bangalore, Karnataka 560043, India
  • Diabetes Thyroid Hormone Research Institute PVT LTD
    Indore, Madhya Pradesh 452001, India
  • Diabetes Action Centre
    Mumbai, Maharashtra 400067, India
  • Gandhi Endocrinology and Diabetes Centre
    Nagpur, Maharashtra 440010, India
  • Endocrine Clinic
    Nashik, Maharashtra 422013, India
  • Grant Medical Foundation
    Pune, Maharashtra 411001, India
  • Fortis Escorts Hospital
    Jaipur, Rajasthan 302017, India
  • B.P.Poddar Hospital and Medical Research Ltd
    Kolkata, West Bengal 700053, India
  • Medwin Hospitals
    Hyderabad, 500001, India
  • Pushpawati Singhania Research Institute
    New Delhi, 110017, India
  • Soroka Medical Centre
    Beer Sheba, 84101, Israel
  • Hillel Yaffe Medical Center
    Hadera, 38100, Israel
  • Rambam Medical Centre
    Haifa, 31096, Israel
  • Wolfson Medical Centre
    Holon, 58100, Israel
  • National Centre for Childhood and Diabetes
    Petach Tikva, 49202, Israel
  • Chaim Sheba Medical Center
    Ramat-Gan, 56261, Israel
  • P. Stradins Clinical University Hospital
    Riga, 1002, Latvia
  • Hospital CIMA Santa Engracia
    San Pedro Garza García, Nuevo Leon 66260, Mexico
  • Hospital Mexico-Americano
    Guadalajara, 44620, Mexico
  • Hospital General de Mexico
    Mexico City, 06726, Mexico
  • Hospital Central
    San Luis Potosí, 78240, Mexico
  • Diabeter Center for Pediatric and Adolescent Diabetes Care and Research
    Rotterdam, 3011TG, Netherlands
  • Samodzielny Publiczny Szpital Kliniczny Akademi Medycznej w Bialymstoku
    Bialystok, 15-276, Poland
  • Oddzial Diabetologiczny Klinika Pediatrii
    Gdansk, 80-952, Poland
  • Wojewodzki Specjalistyczny Szpital Dzieciecy
    Kielce, 25-734, Poland
  • Uniwersytecki Szpital Kliniczny
    Lodz, 91-738, Poland
  • Powiatowy Zespot Szpitali w Olesnicy, Oddzial Chorob Wewnetrznych
    Olesnica, 56400, Poland
  • Klinika Endokrynologii i Diabetologii Wieku Rozwojowego
    Wroclaw, 51-376, Poland
  • I. Szpital Miejski im. Dr. E. Sonnenberga w Lodzi
    Łódź, 92115, Poland
  • S.C. Minimed S.R.L.
    Bacau, 600164, Romania
  • Institutul de Diabet
    Bucharest, 020045, Romania
  • Centrul Medical "Sanatatea ta"
    Bucuresti, 20725, Romania
  • Spitulul Clinic Judetean de Urgenta Cluj
    Cluj-Napoca, 400006, Romania
  • Spitalul Clinic Judetean de Urgenta
    Iasi, 700111, Romania
  • Spitalul Judetean Satu Mare
    Satu Mare, 440055, Romania
  • Hospital Universitari Dr. Josep Trueta de Girona
    Girona, Gerona 17007, Spain
  • Hospital Universitario Principe de Asturias
    Alcala de Henares, Madrid 28805, Spain

Showing the first 100 of 115 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protege Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28. PubMed 21719095 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Jun 2010 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2023, 13 years 6 months after primary completion. A results delay was requested in Nov 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2006
First posted
Oct 11, 2006
Start
Oct 2006
Primary completionActual
Jun 2010
CompletionActual
Aug 2011
Results delay requested
Nov 10, 2011
Results first posted
Dec 5, 2023
Last update
Dec 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00385697
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Oct 11, 2006
Start date
Oct 2006
Primary completion
Jun 2010
Completion
Aug 2011
Results posted
Dec 5, 2023
Last update
Dec 5, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teplizumab

Start the discussion